Evidence map›Paper›PMID 24099361›Full record

ArticleExperimental and clinical psychopharmacology2013

Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy.

Rikki L A Miller, Ganesh A Thakur, William N Stewart, Joshua P Bow, Shama Bajaj, Alexandros Makriyannis, Peter J McLaughlin

Open access · greenAbstract read
In one paragraph

Article in Experimental and clinical psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Rikki L A MillerDepartment of Psychology, Edinboro University of Pennsylvania.
Ganesh A Thakur
William N Stewart
Joshua P Bow
Shama Bajaj
Alexandros Makriyannis
Peter J McLaughlin
Binghamton University · US

Funding

Cannabinergic Medications for Methamphetamine AddictionR37DA023142 · NIDA · NORTHEASTERN UNIVERSITY · PI MAKRIYANNIS, ALEXANDROS · 2007 to 2016
$7.1M
NIDA NIH HHS R37 DA023142
6 · The paper itself

Abstract

The effects of cannabinoid CB1 agonists (including Δ9-tetrahydrocannabinol, the main psychoactive component of marijuana) on attention are uncertain, with reports of impairments, no effects, and occasionally performance enhancements. To better understand these effects, we sought to uncover a role of changing online (within-session) strategy as a possible mediator of the effects of the novel, potent CB1 agonist AM 4054, on a model of sustained attention in male Sprague-Dawley rats. In this operant, two-choice reaction time (RT) task, AM 4054 decreased accuracy in an asymmetric manner; that is, performance was spared on one lever but impaired on the other. Furthermore, this pattern was enhanced by the outcome of the previous trial such that AM 4054 strengthened a win-stay strategy on the "preferred" lever and a lose-shift strategy on the "nonpreferred" lever. This pattern is often found in tests of expectancy; therefore, in a second experiment AM 4054 enhanced expectancy that we engendered by altering the probability of the two stimulus cues. Accuracy was impaired in reporting the less frequent cue, but only after two or more presentations of the more frequent cue. Taking the results of the experiments together, AM 4054 engendered expectancy by increasing the role of previous trial location and outcome on performance of future trials, diminishing stimulus control (and therefore, accuracy). This novel effect of CB1 receptor agonism may contribute to the deleterious effects of cannabinoids on attention.

Indexed as

AdamantaneAnimalsAttentionCannabinoid Receptor AgonistsCannabinolConditioning, OperantCuesMaleRatsReaction TimeReceptor, Cannabinoid, CB1UncertaintyVision, Ocular9-(hydroxymethyl)-3-(1-adamantyl)hexahydrocannabinolAdamantaneCannabinoid Receptor AgonistsCannabinolReceptor, Cannabinoid, CB1

Identifiers

PMID24099361
PMCPMC4006576
OpenAlexW2333602769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.